newsTherapeutic-first for cold agglutinin disease haemolytic anaemia21 November 2022 | By Catherine Eckford (European Pharmaceutical Review)The European Commission has approved Enjaymo®, the first-and-only approved therapeutic for haemolytic anaemia in adults with cold agglutinin disease.
newsFDA grants priority review to Biologics License Application for sutimlimab20 May 2020 | By Victoria Rees (European Pharmaceutical Review)The FDA has granted priority review of the Biologics License Application for sutimlimab to treat haemolysis in patients with cold agglutinin disease (CAD).